Long non-coding RNA SNHG1/microRNA-195-5p/Yes-associated protein axis affects the proliferation and metastasis of gastric cancer via the Hippo signaling pathway

Cheng, Fahui; Wang, Li; Yi, Shengen; Liu, Ganglei

doi:10.1007/s10142-022-00876-2

Cited by 8 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Cheng et al. ( 28 ) showed that SNHG1 downregulation inhibited metastasis of GC cells through the miR-195-5p/YAP1 axis, thereby suppressing the development of brain metastases. In addition, TGF-β also plays an important role in tumor metastasis and acquisition of immune escape.…”

Section: Mechanism Of Gc Brain Metastasismentioning

confidence: 99%

Gastric cancer with brain metastasis: from molecular characteristics and treatment

Zhu,

Zhou,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Gastric cancer is one of the cancers with increasing incidence and ranks fourth globally among the most frequent causes of cancer-related mortality. Early gastric cancer is often asymptomatic or presents with atypical symptoms, and the majority of patients present with advanced disease upon diagnosis. Brain metastases are present in approximately 1% of gastric cancer patients at the time of diagnosis, which significantly contributed to the overall mortality of the disease worldwide. Conventional therapies for patients with brain metastases remain limited and the median overall survival of patients is only 8 months in advanced cases. Recent studies have improved our understanding of the molecular mechanisms underlying gastric cancer brain metastases, and immunotherapy has become an important treatment option in combination with radiotherapy, chemotherapy, targeted therapy and surgery. This review aims to provide insight into the cellular processes involved in gastric cancer brain metastases, discuss diagnostic approaches, evaluate the integration of immune checkpoint inhibitors into treatment and prognosis, and explore the predictive value of biomarkers in immunotherapy.

show abstract

Section: Mechanism Of Gc Brain Metastasismentioning

confidence: 99%

Gastric cancer with brain metastasis: from molecular characteristics and treatment

Zhu,

Zhou,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Liu et al [ 39 ] stated that SNHG1 accentuates the influence of DCLK1/Notch1 on EMT by regulating the miR-15b expression. A past study [ 40 ] proved that SNHG1 acts as a ceRNA to sponge miR-195-5p and thereby upregulates the expression of YAP1, which promotes GC cell proliferation and metastasis. In Xu’s study [ 41 ], they noted that silencing SNHG1 effectively inhibits GC cell migration and that the gene serves as a sponge for miR-216b-5p to enhance the HK2 expression.…”

Section: Snhg1 In Various Cancersmentioning

confidence: 99%

“…During epilepsy progression, SNHG1 delays epilepsy progression by regulating the miR-181a/BCL-2 axis in vitro [ 9 ]. More importantly, SNHG1 is intricately linked to cancer and is abnormally expressed in various cancers, including hepatocellular carcinoma (HCC) [ 16 ], breast cancer (BC) [ 19 ], bladder cancer (BLC) [ 20 ], esophageal squamous cell carcinoma (ESCC) [ 23 ], prostate cancer (PCa) [ 27 ], osteosarcoma (OS) [ 28 ], non-small cell lung cancer (NSCLC) [ 33 ], colorectal cancer (CRC) [ 38 ], gastric cancer (GC) [ 40 ], and acute myeloid leukemia (AML) [ 48 ]. As an essential member of the SNHG family, SNHG1 should be systematically reviewed.…”

Section: Introductionmentioning

confidence: 99%

LncRNA SNHG1: role in tumorigenesis of multiple human cancers

Zeng,

Zhou,

Cai

et al. 2023

Cancer Cell Int

View full text Add to dashboard Cite

Small nucleolar RNA host gene 1 (SNHG1) is an important member of the SNHG family. This family is composed of a group of host genes that can be processed into small nucleolar RNAs and play important biological functions. In an oncogenic role, the SNHG1 expression is increased in various cancers, which has immense application prospects in the diagnosis, treatment, and prognosis of malignant tumors. In this review, we have summarized the role and molecular mechanism of SNHG1 in the development of various cancers. In addition, we have emphasized the clinical significance of SNHG1 in cancers in our article. This molecule is expected to be a new marker for potential usage in the diagnosis, prognosis, and treatment of cancer.

show abstract

“…Among lncRNAs, small nucleolar RNA host gene 1 (SNHG1) is a novel oncogenic lncRNA aberrantly expressed in various types of human cancers [ 20 – 28 ], including hepatocellular carcinoma [ 20 , 29 ], esophageal squamous cell carcinoma [ 21 ], gastric cancer [ 23 ], breast cancer [ 24 ], prostate cancer [ 25 ], acute myeloid leukemia [ 26 ], non-small cell lung cancer [ 27 ] and colorectal cancer [ 28 ]. Nevertheless, the roles, mechanisms, and upstream regulator/downstream effectors of SNHG1 in human MIBC invasion and growth have rarely been explored.…”

Section: Introductionmentioning

confidence: 99%

Isorhapontigenin inhibition of basal muscle-invasive bladder cancer attributed to its downregulation of SNHG1 and DNMT3b

Meng,

Yang,

Lin

et al. 2024

BMC Cancer

View full text Add to dashboard Cite

Background Bladder cancer (BC) is among the most prevalent malignant urothelial tumors globally, yet the prognosis for patients with muscle-invasive bladder cancer (MIBC) remains dismal, with a very poor 5-year survival rate. Consequently, identifying more effective and less toxic chemotherapeutic alternatives is critical for enhancing clinical outcomes for BC patients. Isorhapontigenin (ISO), a novel stilbene isolated from a Gnetum found in certain provinces of China, has shown potential as an anticancer agent due to its diverse anticancer activities. Despite its promising profile, the specific anticancer effects of ISO on BC and the underlying mechanisms are still largely unexplored. Methods The anchorage-independent growth, migration and invasion of BC cells were assessed by soft agar and transwell invasion assays, respectively. The RNA levels of SOX2, miR-129 and SNHG1 were quantified by qRT-PCR, while the protein expression levels were validated through Western blotting. Furthermore, methylation-specific PCR was employed to assess the methylation status of the miR-129 promoter. Functional assays utilized siRNA knockdown, plasmid-mediated overexpression, and chemical inhibition approaches. Results Our study demonstrated that ISO treatment significantly reduced SNHG1 expression in a dose- and time-dependent manner in BC cells, leading to the inhibition of anchorage-independent growth and invasion in human basal MIBC cells. This effect was accompanied by the downregulation of MMP-2 and MMP-9 and the upregulation of the tumor suppressor PTEN. Further mechanistic investigations revealed that SOX2, a key upstream regulator of SNHG1, played a crucial role in mediating the ISO-induced transcriptional suppression of SNHG1. Additionally, we found that ISO treatment led to a decrease in DNMT3b protein levels, which in turn mediated the hypomethylation of the miR-129 promoter and the subsequent suppression of SOX2 mRNA 3’-UTR activity, highlighting a novel pathway through which ISO exerts its anticancer effects. Conclusions Collectively, our study highlights the critical role of SNHG1 downregulation as well as its upstream DNMT3b/miR-129/SOX2 axis in mediating ISO anticancer activity. These findings not only elucidate the mechanism of action of ISO but also suggest novel targets for BC therapy.

show abstract

Long non-coding RNA SNHG1/microRNA-195-5p/Yes-associated protein axis affects the proliferation and metastasis of gastric cancer via the Hippo signaling pathway

Cited by 8 publications

References 39 publications

Gastric cancer with brain metastasis: from molecular characteristics and treatment

Gastric cancer with brain metastasis: from molecular characteristics and treatment

LncRNA SNHG1: role in tumorigenesis of multiple human cancers

Isorhapontigenin inhibition of basal muscle-invasive bladder cancer attributed to its downregulation of SNHG1 and DNMT3b

Contact Info

Product

Resources

About